On the portfolio we have some quick news.
Strides Arcolab: Buys Shasun, Gets a 50% Return on Stelis investment Strides will merge with Shasun Pharma, in an all stock deal. Shasun is listed on the BSE/NSE and its shareholders will get 5 shares of Strides for every 16 shares in Shasun. This is an approximately 33% dilution - in the sense, that the merged entity will have 74% Strides shareholders and 26% Shasun.
Shasun has . . .